Research programme: carbon nanotube anticancer therapeutics - Ensysce Biosciences

Drug Profile

Research programme: carbon nanotube anticancer therapeutics - Ensysce Biosciences

Latest Information Update: 11 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ensysce Biosciences
  • Class Doxorubicins; Paclitaxels; Small interfering RNA
  • Mechanism of Action DNA intercalators; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; RNA interference; Tubulin inhibitors; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jul 2015 Preclinical development is ongoing in USA
  • 25 Sep 2012 Ensysce Biosciences receives SBIR grant from the National Institutes of Health for the development of single walled carbon nanotubes for Cancer
  • 06 Jun 2012 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top